My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC - Episode 13

Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

August 19, 2024

Laurence Albiges, MD, PhD, analyzes the long-term follow-up data from the phase 2 KEYNOTE-B61 study, highlighting the observed overall survival (OS) rate associated with adjuvant pembrolizumab.

EP. 1: Evolving Treatment Standards in Non-Clear Cell RCC

EP. 2: Extended Follow Up of KEYNOTE-B61

EP. 3: Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

EP. 4: STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

EP. 5: Case Presentation: 61-year-old male Renal Cell Carcinoma

EP. 6: Use of Combination Regimens in Frontline RCC

EP. 7: Treatment Decision Making in first-line combinations for advanced RCC

EP. 8: AE Management for Combination Regimens in Advanced RCC

EP. 9: AE Management for Combination Regimens in Advanced RCC

EP. 10: Optimizing Treatment in Advanced RCC

EP. 11: Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile

EP. 12: Updates in the Treatment Approach for Non-clear cell RCC

Now Viewing

EP. 13: Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

EP. 14: Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC

EP. 15: Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)

EP. 16: Summary and Forward Looking for RCC

Please discuss long term follow up data from the phase 2 KEYNOTE-B61 study investigatingpembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell RCC.
- Please provide a brief background surrounding KEYNOTE-B61
- How did the response rates compare across histologies?
- Considering the observed OS benefit with adjuvant pembro, do you intend to approach its adjuvant use in a similar or different manner in this treatment setting?